CHICAGO TRUST Co NA lowered its position in C.R. Bard, Inc. (NYSE:BCR) by 19.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,235 shares of the medical instruments supplier’s stock after selling 300 shares during the period. CHICAGO TRUST Co NA’s holdings in C.R. Bard were worth $390,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Havens Advisors LLC acquired a new position in shares of C.R. Bard during the second quarter worth $3,849,000. Pennsylvania Trust Co increased its position in shares of C.R. Bard by 51.6% in the second quarter. Pennsylvania Trust Co now owns 1,880 shares of the medical instruments supplier’s stock worth $594,000 after buying an additional 640 shares during the period. Iberiabank Corp increased its position in shares of C.R. Bard by 44.6% in the second quarter. Iberiabank Corp now owns 3,474 shares of the medical instruments supplier’s stock worth $1,098,000 after buying an additional 1,071 shares during the period. Stock Yards Bank & Trust Co. acquired a new position in shares of C.R. Bard during the second quarter worth $207,000. Finally, Xact Kapitalforvaltning AB increased its position in shares of C.R. Bard by 31.7% in the second quarter. Xact Kapitalforvaltning AB now owns 10,217 shares of the medical instruments supplier’s stock worth $3,230,000 after buying an additional 2,462 shares during the period. 87.79% of the stock is currently owned by hedge funds and other institutional investors.
Shares of C.R. Bard, Inc. (BCR) opened at 318.57 on Friday. The company has a market capitalization of $23.07 billion, a PE ratio of 40.55 and a beta of 0.59. The company has a 50 day moving average price of $311.80 and a 200 day moving average price of $264.06. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $318.96.
C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Sunday, April 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.22. C.R. Bard had a net margin of 15.70% and a return on equity of 48.72%. The business had revenue of $938.80 million during the quarter, compared to analyst estimates of $916.15 million. During the same period in the previous year, the business earned $2.34 EPS. C.R. Bard’s revenue was up 7.5% compared to the same quarter last year. On average, equities research analysts expect that C.R. Bard, Inc. will post $11.78 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, July 20th. C.R. Bard’s payout ratio is 13.21%.
WARNING: “C.R. Bard, Inc. (BCR) Stake Cut by CHICAGO TRUST Co NA” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/07/14/c-r-bard-inc-bcr-stake-cut-by-chicago-trust-co-na.html.
A number of brokerages have weighed in on BCR. BMO Capital Markets reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday. BidaskClub raised C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $353.00 target price on the stock in a research report on Wednesday, June 21st. Raymond James Financial, Inc. downgraded C.R. Bard from a “strong-buy” rating to a “mkt perform” rating in a research report on Wednesday, April 26th. Finally, Wells Fargo & Company downgraded C.R. Bard from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 25th. Ten investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $271.31.
In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the firm’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the transaction, the vice president now directly owns 10,139 shares of the company’s stock, valued at approximately $3,082,256. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.80% of the stock is owned by company insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.